Biolab & Co announces Lucas Cohin as the new CEO of Exzell Pharma, its Canadian operation

The executive takes up the post with a focus on international expansion, alignment of strategies and integration into the group's culture

Biolab & Co has chosen Lucas Cohin as CEO of Exzell Pharma, its Canadian operation. Lucas has been with the group for seven years and takes up the position at a strategic time of international growth for Biolab.

Lucas Cohin has held leadership positions at Biolab, most recently as Operations Superintendent. He has also been at the forefront of important initiatives, such as creating the Business Process Management (BPM) area and coordinating the People Committee of the Board of Directors. He also took part in the process of acquiring Exzell Pharma, which he now leads.

Exzell Pharma was acquired by Biolab & Co in 2022. With 12 years of experience in the Canadian market, Exzell Pharma stands out for its portfolio of natural products and over-the-counter (OTC) medicines for the whole family. Under the leadership of Lucas Cohin, the company aims to move forward with direct sales channels, including the launch of the brand's own e-commerce, expanding Canadian consumers' access to exclusive solutions and consolidated formulations.

In this expansion process, Lucas also highlights the importance of the product lines developed in Brazil and marketed by Exzell in Canada. “The certification of Biolab's manufacturing units and recognized production excellence make it possible to export medicines to one of the most regulated markets in the world. One example is Salinex, manufactured in Brazil and distributed in Canada by Exzell, which shows the high level of technology, innovation and quality that guide the production of our medicines.”.

Another focus of Lucas“ work at the head of Exzell Pharma is to strengthen Biolab's culture, given the plurality of professionals at the Canadian unit. ”This is one of the main challenges, but also a great opportunity, for Brazilian companies with a global presence, like Biolab. Connecting different cultures requires listening, respect and closeness. In Canada, where diversity of origin is a hallmark of society, this process becomes even more relevant and inspiring. We have to structure a unique corporate culture that values differences, brings people closer together and strengthens the sense of belonging among teams." Around 23% of the country's population (8.3 million people) are immigrants.

In three years as part of Biolab & Co, Exzell Pharma has been consolidating its position in the Canadian healthcare market, with continuous growth. “Having a strong presence in such a strategic and highly regulated country strengthens Biolab's international presence and expands our impact in the healthcare sector, enabling us to reach new heights,” says Fabio Amorosino, CEO of Biolab & Co. “We are convinced that under Lucas Cohin we will expand our relevance in that market, opening up new fronts and businesses, as well as advancing our global presence strategy.”.